{"id":"NCT01474109","sponsor":"Actelion","briefTitle":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","officialTitle":"Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2011-11-18","resultsPosted":"2015-01-06","lastUpdate":"2015-01-06"},"enrollment":289,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Sclerosis","Ulcers"],"interventions":[{"type":"DRUG","name":"macitentan 3mg","otherNames":["ACT-064992"]},{"type":"DRUG","name":"macitentan 10mg","otherNames":["ACT-064992"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"macitentan 3mg","type":"ACTIVE_COMPARATOR"},{"label":"macitentan 10mg","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The DUAL-1 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration. All patients completing Period 1 will continue on their original randomized treatment into Period 2, until the last randomized patient has completed Period 1.\n\nPatients will be randomized in a 1:1:1 ratio (macitentan 3mg: macitentan 10mg: placebo).\n\nThe primary objective is to demonstrate the effect of macitentan on the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcers.\n\nOther objectives include:\n\n* the evaluation of the efficacy of macitentan on hand functionality and DU burden at Week 16 in SSc patients with ongoing DU disease.\n* the evaluation of the safety and tolerability of macitentan in these patients.\n* the evaluation of the efficacy of macitentan on time to first DU complication during the entire treatment period.","primaryOutcome":{"measure":"Incidence Rate of New Digital Ulcers (DUs) up to Week 16","timeFrame":"Baseline to week 16","effectByArm":[{"arm":"Macitentan 3mg","deltaMin":0.9082,"sd":null},{"arm":"Macitentan 10mg","deltaMin":0.9567,"sd":null},{"arm":"Placebo","deltaMin":0.8115,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.706"},{"comp":"OG001 vs OG002","p":"0.360"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":77,"countries":["United States","Australia","Belarus","Bulgaria","Canada","Chile","Colombia","Croatia","Czechia","Denmark","Finland","Germany","Hungary","India","Italy","Poland","Russia","Ukraine"]},"refs":{"pmids":["27163986"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":94},"commonTop":["HEADACHE","INFECTED SKIN ULCER","OEDEMA PERIPHERAL","SKIN ULCER","ANAEMIA"]}}